Patient Group Direction: Ciprofloxacin 500mg (Tularemia)
Patient Group Direction (PGD) for the Initial supply of ciprofloxacin 500mg tablets to adults and children aged 12 years and over with known or suspected exposure to tularemia.
Patient Group Direction (PGD) for the Initial supply of ciprofloxacin 500mg tablets to adults and children aged 12 years and over with known or suspected exposure to tularemia.
Patient Group Direction (PGD) for further supply of ciprofloxacin 500mg tablets to adults and children aged 12 years and over with a known or suspected exposure to anthrax.
Patient Group Direction (PGD) for the Initial supply of ciprofloxacin 500mg tablets to adults and children aged 12 years and over with known or suspected exposure to anthrax.
Patient Group Direction (PGD) for the initial supply of ciprofloxacin tablets or suspension to children aged under 12 years of age with known or suspected exposure to anthrax.
Patient Group Direction (PGD) for further supply of ciprofloxacin tablets or suspension to children aged under 12 years of age with known or suspected exposure to tularemia.
Patient Group Direction (PGD) for the initial supply of ciprofloxacin 500mg tablets to adults and children aged 12 years and over with known or suspected exposure to plague (Yersinia pestis).
Patient Group Direction (PGD) for the further supply of ciprofloxacin 500mg tablets to adults and children aged 12 years and over with known or suspected exposure to anthrax.
Patient Group Direction (PGD) for the initial supply of ciprofloxacin tablets or suspension to children aged under 12 years of age with known or suspected exposure to tularemia.
Patient Group Direction (PGD) for the initial supply of ciprofloxacin tablets or suspension to children aged under 12 years of age with known or suspected exposure to plague (Yersinia pestis).
Patient Group Direction (PGD) for further supply of ciprofloxacin tablets or suspension to children aged under 12 years of age with known or suspected exposure to anthrax.